Researchers discovers new class of Alzheimer's drug

The Roskamp Institute has unveiled its research into a new class of drugs that is designed to reduce the production of the pathological protein linked to Alzheimer's. The finding that NF-kB controls B-amyloid production means that NF-kB inhibitors might be developed as anti-Alzheimer drugs. One such example is Celastrol, which is researched in the Roskamp Institute's publication, and is available as a food supplement but has never been formally tested in Alzheimer's.

"When B-amyloid builds up in humans, patients develop Alzheimer's disease," said Dr. Michael Mullan, Director of the Roskamp Institute. "By stopping its production we can potentially stop the disease. We have found a whole family of drugs that can stop the production of B-amyloid, giving many companies working on NF-kB inhibitors the opportunity to test these types of drugs in Alzheimer's."

- check out this release for more on the discovery

Related Articles:
Study shows that Alzheimer's drugs don't work. Report
Enzyme essential to preventing Alzheimer's. Report
Gene abnormality linked to Alzheimer's. Report
Marijuana may help prevent Alzheimer's. Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.